Autophagy mediated danger signaling regulates tumor immunosurveillance and may potentiate the effects of anti-cancer immunotherapy through increased adjuvanticity

2020 ◽  
pp. 119-140
Author(s):  
Maria Lie Lotsberg ◽  
Sandy Chen ◽  
Sushil Dhakal ◽  
James B. Lorens ◽  
Bruce Baguley ◽  
...  
Keyword(s):  
Cancer Immunotherapy ◽  
Tumor Immunosurveillance ◽  
Anti Cancer

P53 as a target for anti-cancer immunotherapy

1997 ◽  
Vol 3 (4) ◽  
pp. 160-167 ◽  
Author(s):  
Hailei L. Chen ◽  
David P. Carbone
Keyword(s):  
Cancer Immunotherapy ◽  
Anti Cancer

scholarly journals Autoimmune Responses in Oncology: Causes and Significance

2021 ◽  
Vol 22 (15) ◽  
pp. 8030
Author(s):  
Halin Bareke ◽  
Pablo Juanes-Velasco ◽  
Alicia Landeira-Viñuela ◽  
Angela-Patricia Hernandez ◽  
Juan Jesús Cruz ◽  
...  
Keyword(s):  
Cancer Immunotherapy ◽  
Protein Microarrays ◽  
Cross Reactivity ◽  
Fine Tuning ◽  
Cancer Treatments ◽  
Aberrant Expression ◽  
Specificity And Sensitivity ◽  
Anti Cancer ◽  
Life Threatening ◽  
Considerable Impact

Specific anti-tumor immune responses have proven to be pivotal in shaping tumorigenesis and tumor progression in solid cancers. These responses can also be of an autoimmune nature, and autoantibodies can sometimes be present even before the onset of clinically overt disease. Autoantibodies can be generated due to mutated gene products, aberrant expression and post-transcriptional modification of proteins, a pro-immunogenic milieu, anti-cancer treatments, cross-reactivity of tumor-specific lymphocytes, epitope spreading, and microbiota-related and genetic factors. Understanding these responses has implications for both basic and clinical immunology. Autoantibodies in solid cancers can be used for early detection of cancer as well as for biomarkers of prognosis and treatment response. High-throughput techniques such as protein microarrays make parallel detection of multiple autoantibodies for increased specificity and sensitivity feasible, affordable, and quick. Cancer immunotherapy has revolutionized cancer treatments and has made a considerable impact on reducing cancer-associated morbidity and mortality. However, immunotherapeutic interventions such as immune checkpoint inhibition can induce immune-related toxicities, which can even be life-threatening. Uncovering the reasons for treatment-induced autoimmunity can lead to fine-tuning of cancer immunotherapy approaches to evade toxic events while inducing an effective anti-tumor immune response.

scholarly journals Development of Small-Molecule STING Activators for Cancer Immunotherapy

Biomedicines ◽  
2021 ◽  
Vol 10 (1) ◽  
pp. 33
Author(s):  
Hee Ra Jung ◽  
Seongman Jo ◽  
Min Jae Jeon ◽  
Hyelim Lee ◽  
Yeonjeong Chu ◽  
...  
Keyword(s):  
Cancer Immunotherapy ◽  
Cyclic Gmp ◽  
Therapeutic Potential ◽  
Interferon Response ◽  
Type I ◽  
Anti Cancer ◽  
Cancer Agent ◽  
Sting Pathway

In cancer immunotherapy, the cyclic GMP–AMP synthase–stimulator of interferon genes (STING) pathway is an attractive target for switching the tumor immunophenotype from ‘cold’ to ‘hot’ through the activation of the type I interferon response. To develop a new chemical entity for STING activator to improve cyclic GMP-AMP (cGAMP)-induced innate immune response, we identified KAS-08 via the structural modification of DW2282, which was previously reported as an anti-cancer agent with an unknown mechanism. Further investigation revealed that direct STING binding or the enhanced phosphorylation of STING and downstream effectors were responsible for DW2282-or KAS-08-mediated STING activity. Furthermore, KAS-08 was validated as an effective STING pathway activator in vitro and in vivo. The synergistic effect of cGAMP-mediated immunity and efficient anti-cancer effects successfully demonstrated the therapeutic potential of KAS-08 for combination therapy in cancer treatment.

Improving Anti-cancer Immunotherapy by Simultaneous Targeting Suppressive Tumor Microenvironment

2016 ◽  
Vol 07 (03) ◽  
Author(s):  
Lukasz Bialkowski ◽  
Kris Thielemans
Keyword(s):  
Tumor Microenvironment ◽  
Cancer Immunotherapy ◽  
Anti Cancer

scholarly journals Imaging of T-cells and their responses during anti-cancer immunotherapy

Theranostics ◽  
2019 ◽  
Vol 9 (25) ◽  
pp. 7924-7947 ◽  
Author(s):  
Massis Krekorian ◽  
Gilbert O. Fruhwirth ◽  
Mangala Srinivas ◽  
Carl G. Figdor ◽  
Sandra Heskamp ◽  
...  
Keyword(s):  
T Cells ◽  
Cancer Immunotherapy ◽  
Anti Cancer

scholarly journals Anti-cancer immunotherapy: breakthroughs and future strategies

2018 ◽  
Vol 41 (1) ◽  
pp. 1-3 ◽  
Author(s):  
Mads Hald Andersen
Keyword(s):  
Cancer Immunotherapy ◽  
Anti Cancer

Abstract 1652: Optogenetic immunoengineering to develop improved anti-cancer immunotherapy

2017 ◽  
Author(s):  
Lian He ◽  
Nhung Nguyen ◽  
Gang Han ◽  
Yun Huang ◽  
Yubin Zhou
Keyword(s):  
Cancer Immunotherapy ◽  
Anti Cancer

scholarly journals Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy

2020 ◽  
Vol 8 ◽  
Author(s):  
Daria S. Chulpanova ◽  
Kristina V. Kitaeva ◽  
Andrew R. Green ◽  
Albert A. Rizvanov ◽  
Valeriya V. Solovyeva
Keyword(s):  
Cancer Immunotherapy ◽  
Future Perspectives ◽  
Anti Cancer ◽  
Molecular Aspects

scholarly journals HSP70-based anti-cancer immunotherapy

2016 ◽  
Vol 12 (10) ◽  
pp. 2529-2535 ◽  
Author(s):  
Irina V. Guzhova ◽  
Boris A. Margulis
Keyword(s):  
Cancer Immunotherapy ◽  
Anti Cancer
Sign in / Sign up

Export Citation Format

Share Document